1 / 27

Planning for the 2005-2006 Influenza Season: Will it be Rain, Shine, or Hurricane?

Planning for the 2005-2006 Influenza Season: Will it be Rain, Shine, or Hurricane?. National Vaccine Advisory Committee June 7, 2005 Washington, DC Raymond A. Strikas, MD Immunization Services Division National Immunization Program. Key Lessons from 2004. Plan with partners

les
Télécharger la présentation

Planning for the 2005-2006 Influenza Season: Will it be Rain, Shine, or Hurricane?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Planning for the 2005-2006 Influenza Season:Will it be Rain, Shine, or Hurricane? National Vaccine Advisory Committee June 7, 2005 Washington, DC Raymond A. Strikas, MD Immunization Services Division National Immunization Program

  2. Key Lessons from 2004 • Plan with partners • Implement public sector direction of allocation/distribution with partners • Offer flexibility to local areas in recommendations’ implementation • Provide real-time information (e.g., BRFSS) • Plan for contingencies – multiple scenarios • Using IND vaccine routinely problematic • Extending vaccination season difficult • Improve vaccine manufacturing capacity

  3. Planning Strategy • Supply-based scenarios • Monitoring • Insurance policies • Communications

  4. Three Scenarios Base Best Worst

  5. Base Case Scenario: Rain

  6. Base Case Scenario: 63M Doses • TIV • sanofi pasteur only • 60 M doses • 50M by end of November • 10M by end of year • LAIV • MedImmune • 3 M doses • Depends on vaccine virus growth characteristics

  7. Best Case Scenario: Shine

  8. Best Case Scenario: >> 63M Doses • TIV • sanofi pasteur • 50 to 60 M doses • Chiron in U.S. market: 25M-30M doses • GSK licensed: 10 M doses • LAIV: 3 M doses

  9. Worst Case Scenario: Hurricane

  10. Worst Case Scenario: << 63M Doses • Sanofi pasteur production failure • No other TIV manufacturer in the U.S. market • Result – substantially fewer TIV doses than last season

  11. Planning Activities

  12. 2005-06 Influenza Season Planning Group Scope – next season; non-pandemic Charge Identify priority activities Determine who will lead / produce the activity Develop time line Monitor completion Comprehensive and strategic representation Primary planning group for CDC, in collaboration with NVPO, FDA, ASTHO, NACCHO, AIM

  13. Supply Projection Monitoring • Adjusts scenario likelihoods • NVPO, FDA, and CDC activity • Process: calls to manufacturers • Production milestones • Regulatory milestones

  14. Prioritization Recommendation Development • Last season, priorities developed in an emergency ACIP session • ACIP Influenza Working Group met in January to sub-prioritize for next season • Four work groups • Disease impact (Kathy Neuzil Lead) • Disease reduction from vaccination (Kristin Nichol Lead) • Herd Immunity (Arnold Monto Lead) • Economic aspects (Lisa Prosser Lead) • ACIP approved the sub-prioritization recommendations in February

  15. Proposed ACIP Priority Groups for Influenza Vaccination, 2005-06

  16. Concepts • No use of tiering when supply is adequate • However, proposed tiering to be published if necessary • Three tiers based on U.S. rates of influenza-associated mortality & hospitalization • During influenza vaccine shortages • Will recommend tiered vaccination approach • Tier 1 should be vaccinated preferentially, followed by Tier 2, and then Tier 3.

  17. Concepts • If local vaccine supply is extremely limited, • vaccinate Tier 1A before all other groups. • Otherwise, Tiers 1A, 1B, & 1C • Considered equivalent • Should vaccinate simultaneously. • Encourage LAIV for eligible persons in Tier 1C, Tier 2, & Tier 3 • Local application of tiering based on local supply

  18. Pre-Booking and Distribution

  19. Two-Tiered TIV Pre-Booking • Proposed by sanofi pasteur • Request # doses for targeted groups and total # of doses to purchase • Allows public health considerations into vaccine sales

  20. Vaccine Distribution • Predominant strategy has been partial orders to all customers • Advantage: more vaccination early • Was important last season • Two-tiered pre-booking allows public health targeting into initial distribution • Initial distribution to targeted populations • May smooth distribution and allow targeted individuals first access to vaccine

  21. IND Vaccine in Routine Program • Challenges • IND not optimized for routine use • Need to use IRB • Co-PI • Insurance carriers experience limited • A need for routine IND vaccine use argues for different mechanisms to use imported (unlicensed) vaccine

  22. Two Vaccine Insurance Policies • Vaccine stockpile • Purpose: late season demand in excess of vaccine supply • For all three scenarios • Supported by VFC program • Monovalent bulk production solicitation • Purchases maximum number of doses for given amount of funding • For use in worst case scenario • Takes time to combine and package • Could be licensed or unlicensed

  23. Live Attenuated Influenza Vaccine • Useful in all three scenarios • Each LAIV dose spares a TIV dose • Even in subprioritization situation, LAIV has many uses • Health care workers • Military • Household contacts

  24. Planning Decisions

  25. Supply-Based Scenarios 2005-06

  26. 2005-06 Season Concerns • Will demand suffer setback from this past season? • Will private providers retain interest in vaccinating? • Will we be able to communicate the complex messages required for scenario-based planning?

  27. Longer Term Considerations • Increasing vaccine demand, group by group, with an enhanced public health workforce • Developing science basis for broader recommendations (e.g., cost effectiveness) • Stabilizing and diversifying vaccine supply • Selective use of tiering strategies • Pandemic preparedness

More Related